The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...

"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

The US drugs regulator has approved the sale of a new nasal spray to treat depression. Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended ...

"This provides further evidence for the use of esketamine nasal spray in this difficult-to-treat population and offers hope for the millions of people affected by TRD," he added. Analysts at ...

An esketamine-based nasal spray antidepressant for adults is under review in the US following a filing from Johnson & Johnson's pharma unit. Janssen has submitted a filing for esketamine to the US ...

Esketamine for TRD demonstrated efficacy in reducing depressive symptoms and did not significantly differ based on TMS treatment history.

Results, published in CNS Spectrums, showed a significant improvement in symptoms for those taking a new OAD with esketamine ...

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.

In April, she’d begun to use a topical nasal-spray decongestant. The over-the-counter (OTC) drug worked like a charm. By summer, she was still using the spray daily. Yet it was helping for ...